Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET) (KARMET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03781791
Recruitment Status : Recruiting
First Posted : December 20, 2018
Last Update Posted : January 6, 2021
Information provided by (Responsible Party):
Enterin Inc.

Brief Summary:

This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled study. Approximately 72 patients will be randomized 3:1 to treatment or placebo, with approximately 54 patients allocated to receive the active investigational product and approximately 18 patients allocated to receive placebo.

- Study Update-

Amendment 3 - In this amendment, an additional 80 patients (approximately) will be randomized 1:1 to treatment or placebo (double-blind) with approximately 40 subjects allocated to each group.

Condition or disease Intervention/treatment Phase
Constipation Parkinson Disease Drug: Active Investigational Treatment ENT-01 Drug: Placebo Treatment Phase 2

Detailed Description:

The study will be conducted on an out-patient basis. Each patient will have 6 visits to the clinic: a screening visit, a randomization visit, 3 follow up visits, and 1 end of study visit.

Patient randomization will be stratified based upon the baseline weekly complete spontaneous bowel movement rate (CSBM) established during the screening period. Patients will be allowed to adjust their dosing, based upon protocol specifications. Rescue medications will be provided to all patients to ensure they move their bowels on a regular basis.

Patients will also be asked to participate in up to 2 sub-studies: a pk study and/or a stool microbiome study. The first 20 patients to consent to the pk study will have additional blood samples taken at randomization and at 2 follow up visits. The first 20 patients to consent to the stool microbiome study will provide stool samples at randomization and at 2 follow up visits.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 152 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
Actual Study Start Date : December 10, 2018
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : September 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Active Treatment
ENT-01 tablet will be taken once daily by mouth.
Drug: Active Investigational Treatment ENT-01
ENT-01 will be administered in tablet form, once daily.
Other Name: ENT-01

Placebo Comparator: Placebo Treatment
Placebo tablet will be taken once daily by mouth.
Drug: Placebo Treatment
Placebo will be administered in tablet form, once daily.

Primary Outcome Measures :
  1. Incidence of Treatment Related Adverse Events-Safety Endpoint [ Time Frame: Through Study treatment up to 10 weeks ]
    The number of treatment related adverse events as reported and assessed by NCI CTCAE v.4.3.

  2. Incidence of Treatment Related Adverse Event-Tolerability Endpoints [ Time Frame: Through Study treatment Dosing Period up to 10 weeks ]
    The number of treatment related adverse events as reported and assessed by NCI CTCAE v.4.3.

  3. Change in baseline weekly CSBM-Primary Efficacy Endpoint [ Time Frame: Through Study Treatment Dosing Period up to 10 weeks ]
    Change from participant's weekly CSBM baseline rate during treatment fixed Dose period.

Secondary Outcome Measures :
  1. Change in participant constipation severity from baseline-Secondary Efficacy Endpoints [ Time Frame: Through Study Treatment Dosing Period up to 10 weeks ]
    Participant reported change from baseline as assessed according to Bristol Stool rating scale (0-5) of increasing severity of ease of bowel evacuation.

Other Outcome Measures:
  1. Change in baseline stool Microbiome - Exploratory Outcome [ Time Frame: Through Study Treatment Dosing Period and Completion up to 24 weeks ]
    Collection of participant baseline intestinal microbiome condition as observed in stool to on treatment related effect of ENT-01 on stool microbiome

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects aged 30-90 years, both genders
  2. Subjects must provide written informed consent and be willing and able to comply with study procedures.
  3. Subjects must be diagnosed with Parkinson's Disease defined as the presence of at least three of the following cardinal features, in the absence of alternative explanations or atypical features: rest tremor, rigidity, bradykinesia and/or akinesia, postural and gait abnormalities.
  4. There are insufficient criteria for Irritable Bowel Syndrome (IBS)
  5. Constipation which has been present for over 6 months and is unresponsive to first line, typically over the counter treatments such as Milk of Magnesia (1g), Miralax (17g in 8 ounces of water) or the equivalent at least once weekly with an inconsistent response over a 6-week period or the subject is dissatisfied with first line treatments.
  6. Body mass index (BMI) of 18-40 kg/m2
  7. Subjects must fulfill Rome IV criteria for functional constipation which includes 2 or more of the following:

    1. Straining during at least 25% of defecations
    2. Lumpy or hard stools in at least 25% of defecations
    3. Sensation of incomplete evacuation for at least 25% of defecations
    4. Sensation of anorectal obstruction/blockage for at least 25% of defecations
    5. Manual maneuvers to facilitate at least 25% of defecations (e.g., digital evacuation, support of the pelvic floor)
  8. Self-report of fewer than 3 complete spontaneous bowel movements per week
  9. Loose stools are rarely present without the use of laxatives
  10. Subjects must be able to read, understand, and accurately record data into the diary to guarantee full participation in the study.
  11. Female subjects must have negative serum or urine pregnancy tests and must not be lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of birth control must be used throughout the study. A vasectomized partner will be allowed as one in conjunction with another single-barrier method.
  12. Female subjects unable to bear children must have this documented in the CRF (i.e., tubal ligation, hysterectomy, or postmenopausal [defined as a minimum of one year since the last menstrual period]). Post-menopausal status will be confirmed by follicle stimulating hormone (FSH) in women less than 60 years of age.

Exclusion Criteria:

  1. Unable or unwilling to provide informed consent or to comply with study procedures.
  2. Diagnosis of secondary constipation beyond that of Parkinson's Disease
  3. Review of Screening Diaries indicates fewer than 11 days of diary completion and/or 3 or more complete spontaneous bowel movements (CSBM) per week based upon the average CSBM rate reported during the Screening Period
  4. A compromised gastrointestinal system which includes:

    1. Structural, metabolic, or functional GI diseases or disorders
    2. Acute GI illness within 2 weeks of the screening visit
    3. History of major GI surgery within 30 days of the screening visit (a history of cholecystectomy, polypectomy, hernia repair or appendicectomy are not exclusionary as long as they were performed more than 30 days before the screening visit)
  5. Unable or unwilling to withdraw from laxatives, opiates, clonazepam, or any medications which may cause constipation, 2 weeks prior to the dose adjustment period and throughout the rest of the study.
  6. Unable or unwilling to withdraw from proton pump inhibitors and antacids at the end of the screening period.
  7. Unable or unwilling to withdraw from pimavanserin during the study.
  8. Any clinically significant abnormalities on screening laboratories or physical examination requiring further evaluation or treatment.
  9. Neurological disorder other than Parkinson's Disease that in the opinion of the investigator might interfere with the conduct of the study.
  10. On treatment with intra-jejunal dopamine or carbidopa/levodopa (i.e. Duopa).
  11. Subjects starting a new Parkinson's Disease medication or modifying an existing medication within 2 weeks prior to enrollment.
  12. Unable to maintain a stable diet regimen.
  13. Subjects with a cognitive impairment that preclude them from understanding the informed consent.
  14. Subjects placed under legal guardianship.
  15. Females who are pregnant or breastfeeding.
  16. History of excessive alcohol use or substance abuse.
  17. Participation in an investigational drug trial within the month prior to dosing in the present study.
  18. Any other reason, which, in the opinion of the investigator, would confound proper interpretation of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03781791

Layout table for location contacts
Contact: Denise Barbut, MD, FRCP 215 634 9243

Show Show 52 study locations
Sponsors and Collaborators
Enterin Inc.
Layout table for investigator information
Study Chair: Michael Zasloff, MD PhD Enterin Inc.
Study Director: Denise Barbut, MD, FRCP Enterin Inc.
Layout table for additonal information
Responsible Party: Enterin Inc. Identifier: NCT03781791    
Other Study ID Numbers: ENT-01-030
First Posted: December 20, 2018    Key Record Dates
Last Update Posted: January 6, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Signs and Symptoms, Digestive